Knight Therapeutics (TSE:GUD) Reaches New 1-Year High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD) shares reached a new 52-week high on Thursday . The company traded as high as C$8.04 and last traded at C$7.86, with a volume of 37887 shares changing hands. The stock had previously closed at C$7.51.

Knight Therapeutics Stock Up 10.8%

The company has a debt-to-equity ratio of 10.15, a current ratio of 2.39 and a quick ratio of 1.79. The business’s fifty day simple moving average is C$6.99 and its two-hundred day simple moving average is C$6.34. The company has a market cap of C$815.83 million, a PE ratio of -166.40, a PEG ratio of -1,013.50 and a beta of -0.21.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. Knight Therapeutics had a negative net margin of 1.19% and a negative return on equity of 0.70%. The company had revenue of C$147.59 million during the quarter. On average, analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.